More News! 17 Oct 2018 The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech? AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer patent-protected in the EU. Competitors are already taking advantage of it. Humira is an antibody… October 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 26 Mar 2018 Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been… March 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2021 AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research …with targeting tau. Their anti-tau antibody semorinemab yielded both positive and negative results in a phase II trial in people with Alzheimer’s disease. According to one established measure of patient… September 2, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Jan 2025 Singapore’s biotech scene: 7 companies leading the way in 2025 …team to boost platform technology development, and expand its U.S. presence. Hummingbird Bioscience Lead candidate: HMBD-001, an anti-HER3 monoclonal antibody HMBD-001 being tested in phase 1/2a trials in U.K. and… January 14, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2019 German Biotech Raises €7M Series A to Treat Acute Heart Failure 4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was… December 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jun 2020 Belgian mRNA Vaccine for Covid-19 Receives €34M Series B Boost …have some possible drawbacks. Antibody responses can decline quickly if not backed up by T helper cells, also known as ‘memory’ cells, and it’s possible that a weak antibody response… June 18, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2018 UK Biotech Wins Major Grant to Manage Chronic Pain With Antibodies …a grant of £556K (€633K) from Innovate UK to develop its antibody platform, KnotBody, for therapeutic applications in chronic pain management. Iontas’ antibody approach could provide an alternative to opioids,… May 31, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Dec 2018 Looking Back on 2018: Our 10 Most Popular Interviews …Phase II. 10. MorphoSys’ CEO tells us what’s next for Europe’s antibody expert After 25 years, MorphoSys finally got over the line in 2017 with the FDA approval of its… December 24, 2018 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 19 Jun 2017 Discussing the Virtual Biotech Model with XO1 Co-Founder Trevor Baglin …A patient presented at my hospital with what’s called a paraprotein, which is sort of a rogue antibody produced by the aging immune system. This antibody targeted exosite 1 of… June 19, 2017 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 May 2025 Interleukin therapeutics: 9 companies to follow in 2025 …The molecule is fused to a targeting antibody fragment that locks it onto CD8+ T cells and leaves other populations largely untouched. AB248 is currently in a phase 1a/1b clinical… May 27, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 11 Dec 2024 Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy? …Valora’s immunotherapies look much like a conventional antibody, but with one of the usual Y-like arms replaced with a lectin domain. While the antibody domain provides precise targeting to specific… December 11, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2020 French Biotech Raises €19M to Hit Phase I with Cancer Immunotherapy …lead cancer immunotherapy into phase I testing. The candidate is an antibody that depletes T regulatory cells, or Tregs, which help tumors to evade the immune system. Alderaan expects to… January 9, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email